Cell kinetics evaluation of colorectal tumors after in vivo administration of bromodeoxyuridine

L. Roncucci, M. Pedroni, A. Scalmati, M. L. Bormiolo, R. Sassatelli, R. Fante, L. Losi, C. Di Gregorio, B. Petocchi, M. Ponz de Leon

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Although several biomarkers have been tested, Dukes' (or TNM) stage at diagnosis is still considered the only prognostic factor of clinical relevance in colorectal cancer. Among the various biomarkers, the fraction of cells engaged in DNA synthesis has been extensively investigated as an indicator of tumor aggressiveness. Bromodeoxyuridine (BUdR) is a nonradioactive thymidine analogue which is incorporated into DNA during the S-phase of cycling cells. In order to evaluate the relationships between cell kinetics and morphologic variables, 500 mg of BUdR were given i.v. to 46 patients with colorectal cancer prior to surgery. After operation, a large tumor sample was taken and processed for immunohistochemical detection of BUdR-labeled cells in various regions of the neoplasm and in normal colorectal mucosa. Smaller superficial tumor specimens were also incubated with 3H-thymidine (3H-TdR) for the autoradiographic identification of labeled cells. In the 43 evaluable tumors, the overall BUdR labeling index (BLI, percent of labeled cells) was significantly higher in carcinoma (20.30 ± 0.86%, SEM) than in normal colonic mucosa (6.51 ± 0.49%). BLIs in central and peripheral regions of carcinoma were closely correlated (r = 0.48, p = 0.003). In 21 neoplasms a high correlation between overall BUdR and 3H-TdR labeling index in the same tumor was observed (r = 0.57, p = 0.007). No evident association between overall BLI and clinical or morphologic parameters of the tumor was seen, including number of capillaries and ras-p21 protein expression. We conclude that BUdR immunostaining after in vivo administration of BUdR is a simple method for studying cell kinetics in various regions of colorectal cancer. BUdR labeling data are comparable to those obtained with in vitro incorporation of 3H-TdR.

Original languageEnglish
Pages (from-to)856-861
Number of pages6
JournalInternational Journal of Cancer
Volume52
Issue number6
DOIs
Publication statusPublished - 1992

Fingerprint

Bromodeoxyuridine
Colorectal Neoplasms
Neoplasms
Thymidine
Mucous Membrane
Biomarkers
Carcinoma
ras Proteins
DNA
S Phase

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cell kinetics evaluation of colorectal tumors after in vivo administration of bromodeoxyuridine. / Roncucci, L.; Pedroni, M.; Scalmati, A.; Bormiolo, M. L.; Sassatelli, R.; Fante, R.; Losi, L.; Di Gregorio, C.; Petocchi, B.; Ponz de Leon, M.

In: International Journal of Cancer, Vol. 52, No. 6, 1992, p. 856-861.

Research output: Contribution to journalArticle

Roncucci, L, Pedroni, M, Scalmati, A, Bormiolo, ML, Sassatelli, R, Fante, R, Losi, L, Di Gregorio, C, Petocchi, B & Ponz de Leon, M 1992, 'Cell kinetics evaluation of colorectal tumors after in vivo administration of bromodeoxyuridine', International Journal of Cancer, vol. 52, no. 6, pp. 856-861. https://doi.org/10.1002/ijc.2910520604
Roncucci, L. ; Pedroni, M. ; Scalmati, A. ; Bormiolo, M. L. ; Sassatelli, R. ; Fante, R. ; Losi, L. ; Di Gregorio, C. ; Petocchi, B. ; Ponz de Leon, M. / Cell kinetics evaluation of colorectal tumors after in vivo administration of bromodeoxyuridine. In: International Journal of Cancer. 1992 ; Vol. 52, No. 6. pp. 856-861.
@article{e9ccae16658d496db9a760b845b446b7,
title = "Cell kinetics evaluation of colorectal tumors after in vivo administration of bromodeoxyuridine",
abstract = "Although several biomarkers have been tested, Dukes' (or TNM) stage at diagnosis is still considered the only prognostic factor of clinical relevance in colorectal cancer. Among the various biomarkers, the fraction of cells engaged in DNA synthesis has been extensively investigated as an indicator of tumor aggressiveness. Bromodeoxyuridine (BUdR) is a nonradioactive thymidine analogue which is incorporated into DNA during the S-phase of cycling cells. In order to evaluate the relationships between cell kinetics and morphologic variables, 500 mg of BUdR were given i.v. to 46 patients with colorectal cancer prior to surgery. After operation, a large tumor sample was taken and processed for immunohistochemical detection of BUdR-labeled cells in various regions of the neoplasm and in normal colorectal mucosa. Smaller superficial tumor specimens were also incubated with 3H-thymidine (3H-TdR) for the autoradiographic identification of labeled cells. In the 43 evaluable tumors, the overall BUdR labeling index (BLI, percent of labeled cells) was significantly higher in carcinoma (20.30 ± 0.86{\%}, SEM) than in normal colonic mucosa (6.51 ± 0.49{\%}). BLIs in central and peripheral regions of carcinoma were closely correlated (r = 0.48, p = 0.003). In 21 neoplasms a high correlation between overall BUdR and 3H-TdR labeling index in the same tumor was observed (r = 0.57, p = 0.007). No evident association between overall BLI and clinical or morphologic parameters of the tumor was seen, including number of capillaries and ras-p21 protein expression. We conclude that BUdR immunostaining after in vivo administration of BUdR is a simple method for studying cell kinetics in various regions of colorectal cancer. BUdR labeling data are comparable to those obtained with in vitro incorporation of 3H-TdR.",
author = "L. Roncucci and M. Pedroni and A. Scalmati and Bormiolo, {M. L.} and R. Sassatelli and R. Fante and L. Losi and {Di Gregorio}, C. and B. Petocchi and {Ponz de Leon}, M.",
year = "1992",
doi = "10.1002/ijc.2910520604",
language = "English",
volume = "52",
pages = "856--861",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Cell kinetics evaluation of colorectal tumors after in vivo administration of bromodeoxyuridine

AU - Roncucci, L.

AU - Pedroni, M.

AU - Scalmati, A.

AU - Bormiolo, M. L.

AU - Sassatelli, R.

AU - Fante, R.

AU - Losi, L.

AU - Di Gregorio, C.

AU - Petocchi, B.

AU - Ponz de Leon, M.

PY - 1992

Y1 - 1992

N2 - Although several biomarkers have been tested, Dukes' (or TNM) stage at diagnosis is still considered the only prognostic factor of clinical relevance in colorectal cancer. Among the various biomarkers, the fraction of cells engaged in DNA synthesis has been extensively investigated as an indicator of tumor aggressiveness. Bromodeoxyuridine (BUdR) is a nonradioactive thymidine analogue which is incorporated into DNA during the S-phase of cycling cells. In order to evaluate the relationships between cell kinetics and morphologic variables, 500 mg of BUdR were given i.v. to 46 patients with colorectal cancer prior to surgery. After operation, a large tumor sample was taken and processed for immunohistochemical detection of BUdR-labeled cells in various regions of the neoplasm and in normal colorectal mucosa. Smaller superficial tumor specimens were also incubated with 3H-thymidine (3H-TdR) for the autoradiographic identification of labeled cells. In the 43 evaluable tumors, the overall BUdR labeling index (BLI, percent of labeled cells) was significantly higher in carcinoma (20.30 ± 0.86%, SEM) than in normal colonic mucosa (6.51 ± 0.49%). BLIs in central and peripheral regions of carcinoma were closely correlated (r = 0.48, p = 0.003). In 21 neoplasms a high correlation between overall BUdR and 3H-TdR labeling index in the same tumor was observed (r = 0.57, p = 0.007). No evident association between overall BLI and clinical or morphologic parameters of the tumor was seen, including number of capillaries and ras-p21 protein expression. We conclude that BUdR immunostaining after in vivo administration of BUdR is a simple method for studying cell kinetics in various regions of colorectal cancer. BUdR labeling data are comparable to those obtained with in vitro incorporation of 3H-TdR.

AB - Although several biomarkers have been tested, Dukes' (or TNM) stage at diagnosis is still considered the only prognostic factor of clinical relevance in colorectal cancer. Among the various biomarkers, the fraction of cells engaged in DNA synthesis has been extensively investigated as an indicator of tumor aggressiveness. Bromodeoxyuridine (BUdR) is a nonradioactive thymidine analogue which is incorporated into DNA during the S-phase of cycling cells. In order to evaluate the relationships between cell kinetics and morphologic variables, 500 mg of BUdR were given i.v. to 46 patients with colorectal cancer prior to surgery. After operation, a large tumor sample was taken and processed for immunohistochemical detection of BUdR-labeled cells in various regions of the neoplasm and in normal colorectal mucosa. Smaller superficial tumor specimens were also incubated with 3H-thymidine (3H-TdR) for the autoradiographic identification of labeled cells. In the 43 evaluable tumors, the overall BUdR labeling index (BLI, percent of labeled cells) was significantly higher in carcinoma (20.30 ± 0.86%, SEM) than in normal colonic mucosa (6.51 ± 0.49%). BLIs in central and peripheral regions of carcinoma were closely correlated (r = 0.48, p = 0.003). In 21 neoplasms a high correlation between overall BUdR and 3H-TdR labeling index in the same tumor was observed (r = 0.57, p = 0.007). No evident association between overall BLI and clinical or morphologic parameters of the tumor was seen, including number of capillaries and ras-p21 protein expression. We conclude that BUdR immunostaining after in vivo administration of BUdR is a simple method for studying cell kinetics in various regions of colorectal cancer. BUdR labeling data are comparable to those obtained with in vitro incorporation of 3H-TdR.

UR - http://www.scopus.com/inward/record.url?scp=0026621104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026621104&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910520604

DO - 10.1002/ijc.2910520604

M3 - Article

C2 - 1459724

AN - SCOPUS:0026621104

VL - 52

SP - 856

EP - 861

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -